2022
DOI: 10.1128/mbio.02979-21
|View full text |Cite
|
Sign up to set email alerts
|

The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines

Abstract: The emergence of several new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in recent months has raised concerns around the potential impact on ongoing vaccination programs. Data from clinical trials and real-world evidence suggest that current vaccines remain highly effective against the alpha variant (B.1.1.7), while some vaccines have reduced efficacy and effectiveness against symptomatic disease caused by the beta variant (B.1.351) and the delta variant (B.1.617.2); however, effec… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
106
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 138 publications
(119 citation statements)
references
References 182 publications
(217 reference statements)
2
106
0
1
Order By: Relevance
“…The recently emerged Omicron (B.1.1.529) VOC contains a significantly larger number of mutations that result in neutralization resistance against many therapeutic and convalescent plasma antibodies ( 56 , 57 ). Increased transmissibility of VOC has also been reported; Alpha (B.1.1.7) VOC was determined to be 43-90% more transmissible than the Washington strain, Delta (B.1.617.2) VOC was determined to be 60% more transmissible than Alpha (B.1.1.7) VOC, and Omicron (B.1.1.529) VOC was determined to be 100% more transmissible than Delta (B.1.617.2) VOC ( 57 59 ). Further, population-level analysis has identified a significant increase in reinfection risk associated with Omicron (B.1.1.529), but not Beta (B.1.351) or Delta (B.1.617.2) VOC ( 60 ).…”
Section: Discussionmentioning
confidence: 99%
“…The recently emerged Omicron (B.1.1.529) VOC contains a significantly larger number of mutations that result in neutralization resistance against many therapeutic and convalescent plasma antibodies ( 56 , 57 ). Increased transmissibility of VOC has also been reported; Alpha (B.1.1.7) VOC was determined to be 43-90% more transmissible than the Washington strain, Delta (B.1.617.2) VOC was determined to be 60% more transmissible than Alpha (B.1.1.7) VOC, and Omicron (B.1.1.529) VOC was determined to be 100% more transmissible than Delta (B.1.617.2) VOC ( 57 59 ). Further, population-level analysis has identified a significant increase in reinfection risk associated with Omicron (B.1.1.529), but not Beta (B.1.351) or Delta (B.1.617.2) VOC ( 60 ).…”
Section: Discussionmentioning
confidence: 99%
“…Since the early stage of the pandemic, the evolution of SARS-CoV-2 has been shaped by selection pressures from vaccination, antiviral therapies, and other mitigation strategies [ 7 , 8 , 10 , 53 ]. The general population in many countries has been protected from severe disease through the distribution of vaccines, while the immunosuppressed population may still be at risk for severe disease despite their vaccination status [ 9 , 34 , 54 ].…”
Section: Discussionmentioning
confidence: 99%
“…Some vaccines have shown lower efficacy against the delta variant (B.1.617.2) and the omicron variant (B.1.1.529) [17] . Booster shots with mRNA vaccines restored protection against the omicron variant (B.1.1.529) [17] …”
Section: Figurementioning
confidence: 99%
“…In a study on 5 year‐olds and under which excludes the compounding of vaccination and past infections, the symptoms of Omicron infected patients were substantially less severe than those infected with the Delta variant [16] . Some vaccines have shown lower efficacy against the delta variant (B.1.617.2) and the omicron variant (B.1.1.529) [17] . Booster shots with mRNA vaccines restored protection against the omicron variant (B.1.1.529) [17] …”
Section: Figurementioning
confidence: 99%